"Visit the UCLA Health website for coronavirus updates."

During the past decade, Jules Stein Eye Institute conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 14 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 7 clinical trials were completed. i.e. 41.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Jules Stein Eye Institute" #1 sponsor was "University of California, Los Angeles" with 12 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "Astellas Institute for Regenerative Medicine" with 5 trials sponsored, "JHSPH Center for Clinical Trials" with 4 trials sponsored and "National Institute of Allergy and Infectious Diseases (NIAID)" with 4 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jules Stein Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 10 trials as a collaborator, "The Lowy Medical Research Institute Limited" with 3 trials as a collaborator, "Jules Stein Eye Institute" with 2 trials as a collaborator, "Allergan" with 1 trials as a collaborator and "American Academy of Optometry (funding)" with 1 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Jules Stein Eye Institute" are "Cytomegalovirus Retinitis" (6 trials), "Geographic Atrophy" (6 trials), "HIV Infections" (6 trials), "Choroidal Melanoma" (5 trials) and "Ocular Melanoma" (4 trials). Many other conditions were trialed in "Jules Stein Eye Institute" in a lesser frequency.

Most popular intervention types in "Jules Stein Eye Institute" are "Drug" (38 trials), "Biological" (11 trials), "Device" (11 trials), "Other" (7 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "MA09-hRPE" (4 trials), "Sham" (4 trials), "Lampalizumab" (3 trials), "Placebo" (3 trials) and "Aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Jules Stein Eye Institute" are 74 trials for "All" genders.

Currently, there are NaN active trials in "Jules Stein Eye Institute". undefined are not yet recruiting, 12 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Jules Stein Eye Institute, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Jules Stein Eye Institute, 9 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 11 trials that are defined as “Not Applicable".

Jules Stein Eye Institute has several departments that took part in Clinical trials: "UCLA Gonda Diabetes Center" - 2 trials, "UCLA Department of Medicine Division of Endocrinology" - 2 trials, "Olive View- UCLA Center, Dept. Emergency Medicine" - 2 trials, "UCLA Emergency Medical Center" - 2 trials, "UCLA" - 2 trials